CA1224468A - Ortho substituted dihydroxy-2(1h)quinazolinone-1- alkanoic acids - Google Patents

Ortho substituted dihydroxy-2(1h)quinazolinone-1- alkanoic acids

Info

Publication number
CA1224468A
CA1224468A CA000509685A CA509685A CA1224468A CA 1224468 A CA1224468 A CA 1224468A CA 000509685 A CA000509685 A CA 000509685A CA 509685 A CA509685 A CA 509685A CA 1224468 A CA1224468 A CA 1224468A
Authority
CA
Canada
Prior art keywords
methyl
quinazolinone
dimethoxy
carbon atoms
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA000509685A
Other languages
French (fr)
Inventor
Victor T. Bandurco
Dennis M. Mulvey
Seymour D. Levine
Alfonso J. Tobia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ortho Pharmaceutical Corp
Original Assignee
Ortho Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/430,552 external-priority patent/US4490374A/en
Application filed by Ortho Pharmaceutical Corp filed Critical Ortho Pharmaceutical Corp
Priority to CA000509685A priority Critical patent/CA1224468A/en
Application granted granted Critical
Publication of CA1224468A publication Critical patent/CA1224468A/en
Expired legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

ORTHO SUBSTITUTED DIHYDROXY-2(1H)QUINAZOLINONE-1-ALKANOIC
ACIDS

ABSTRACT

The synthesis of substituted quinazolinones is described.
The novel quinazolinones are renal vasodilators and thereby increase renal blood flow, and are useful as cardiovascular agents. The substituted quinazolinones have the following formula wherein R1 is hydrogen, amino or nitro; R2 is hydrogen, alkyl having 1-20 carbon atoms, cycloalkyl having 4-8 carbon atoms, cycloalkylalkyl wherein the cycloalkyl group has 4-8 carbon atoms and the alkyl group has 1-3 carbon atoms, haloalkyl having 1-3 halogen atoms and 1-4 carbon atoms and the halogen is chloro, bromo or fluoro, and bicycloalkyl such as norbornyl and norbornylmethyl; R3 and R4 may be the same or different and are hydrogen, lower alkyl having 1-6 carbon atoms, aryl and substituted aryl such as phenyl, 2-, 3-, and 4-pyridyl, o-, m-, and p-hydroxyphenyl, halophenyl such as p-chlorophenyl, p-fluorophenyl, o-chlorophenyl, 2,4-difluorophenyl, lower alkoxyphenyl such as methoxy, ethoxy, and butoxyphenyl, alkylphenyl wherein the alkyl group contains 1-6 carbon atoms; X is benzyl, carboxy, carboalkoxy wherein the alkoxy group has 1-3 carbon atoms, cyano, carboxamido, methanesulfonyl, formyl, aroyl, such as benzoyl, substitu-ted benzoyl wherein the substituent is an alkyl group having 1-4 carbon atoms, heteroaryl such as 2-, 3-, and 4-pyridyl, and 2-thienyl; heteroaroyl, such as 2-, 3-, and 4-pyridoyl, 2-thienoyl, 2-furoyl and 3-(1,2,5-) thiadia-zolyl; R5 is hydrogen, lower alkyl having 1-6 carbons;

benzyl or substituted benzyl wherein the substituent is fluoro, chloro, bromo, alkyl or alkoxy wherein the alkyl group has 1-6 carbon atoms; provided that when R5 is other than hydrogen the compound is a quaternary salt when the 3,4-imine linkage is unsaturated; (the presence of an unsaturated imine linkage between N3 and C4 is optional and N3 may or may not be substituted); Y and Z are hydrogen or hydroxy.

Description

ORTHO SVBSTITUTE~ DIHYDROXY-2(1H)QUINAZOLIMONE-l-ALKANOIC
ACIDS

The present invention relates to substituted quinazoli-nones having functionality at Nl. The substituted q~inazolinones which are the subject of this invention have the following formula ~ = -R5 z~O
R~X

wherein Rl is hydrogen, amino or nitro; R2 is hydrogen, alkyl having 1-20 carbon atoms, cycloalkyl having 4-8 carbon atoms, cycloalkylalkyl wherein the cycloalkyl group has 4-8 carbon atoms and the alkyl group has 1-3 carbon atoms, haloalkyl having 1-3 halogen atoms and 1-4 carbon atoms and the halogen is chloro, bromo or fluoro, and bicycloalkyl such as norbornyl and norbornylmethyl; R3 and R4 may be the same or different and are hydrogen, lower alkyl having 1-6 carbon atoms, aryl and substituted aryl such as phenyl, 2-, 3-, and 4-pyridyl, o~, m~, and E~
hydroxyphenyl, halophenyl such as ~-chlorophenyl, p-fluorophenyl, o-chlorophenyl, 2,4-difluorophenyl, lower alkoxyphenyl such as methoxy, ethoxy, and butoxyphenyl, alkylphenyl wherein the alkyl group contains 1-6 carbon atoms; X is benzyl, carboxy, carboalkoxy wherein the alkoxy group has 1-3 carbon ato~s, cyano, carboxamido, methanesulfonyl, formyl, aroyl, such as benzoyl, substitu-ted benzoyl wherein the substituent is an alkyl group having 1-4 carbon atoms, heteroaryl such as 2-, 3-, and 4-pyridyl, and 2-thienyl; heteroaroyl, such as 2-, 3-, and 4-pyridoyl, 2-thienoyl, 2-furoyl and 3~(1,2,5-) thiadia-zolyl; R5 is hydrogen, lower alkyl having 1-6 carbons;
~1$~

` ORTH-388 benzyl or substituted benzyl wherein the substituent is Eluoro, chloro, bromo, alkyl or alkoxy wherein the alkyl group has 1-6 carbon atoms; provided that when R5 is other than hydrogen the compound is a quaternary salt when the 3,4-imine linkage is unsaturated; (the presence of an unsat~rated imine linkage between N3 and C4 is optional and N3 may or may not be substituted); Y and Z are hydrogen or hydroxy, provided that at least one of Y and Z
is hydroxy (when Y and Z are both hydroxy the hydroxyl groups are positioned adjacent to each other at ei~her the 5,6- or the 6,7- position); and including the alkali metal and alkaline earth metal salts of the phenolic hydroxyls and the carboxy group at N-l and selected amine salts such as the salts of meglumine, piperazine, ~I-methylpiperazine, morpholine and aliphatic amines having 1-5 carbon atoms;
a~inoalcohols such as ethanolamine, 2-amino-1,3-propane-diol and bis(hydroxymethyl)methylamine; and amino acids such as arginine, lysine and ornithine.

The preferred compounds of the present invention are those wherein Rl is hydrogen; R2 is hydrogen, alkyl, cycloalkyl, bicycloalkyl and haloalkyl; R3 and R4 are hydrogen, lower alkyl, aryl and substituted aryl; X is carboxy, carbo-alkoxy, cyano, carboxamido and formyl; R5 is hydrogen, lower alkyl, benzyl, substi~uted benzyl, provided that when R5 is other than hydrogen ~he compound is a quater-nary salt when the 3,4-imine linkage is unsaturated (the unsaturated imine linkage between N3 and C4 is optional and N3 may or may not be substituted); Y and Z are hydro-gen or hydroxy, provided that at least one of Y and Z ishydroxy; and including the alkali metal and alkaline earth metal salts of the phenolic hydroxyls and the carboxy group at Nl and selected amine salts such as the salts of meglumine, piperazine, N-methylpiperazi~e, mor pholine and aliphatic amines having 1-5 carbon atoms, aminoalcohols such as ethanolamine, 2-amino-1,3-propanediol and bis(hydroxymethyl)methylamine; and amino acids such as arginine, lysine and ornithine. When Y and Z are both hydroxy, the hydroxyl groups are positioned adjacent to each other and are located at either the 5,6-or the 6,7-position.

Several 6,7-dialkoxy-~-alkyl 2(1H)quinazolinones have been reported in the literature [Budesinsky et al., _oll.
Czech. Chem. Commun., 37, 2779 (1972); Belgian Patent No.
765947 (1971)]. None of the reported substituted quinazo-linones have hydroxy groups substitu~ed on the benzenering. In addition, the known quinazolinones are not simi-larly substituted at Nl.

The novel quinazolinones of this invention are renal vasodilators. As such they increase renal blood flow and are therefore useful as cardiovascular agents. In addition, some of the compounds and some of the inter~ediates used to prepare the novel quinazolinones possess cardiotonic activity.
The substituted quinazolinones can be synthesized according to the following schematic diagram.

~2~ 61~

R?~

R~ H~O

¦ X~ R3 ¦, R4 0~ ~ ~ Aci~ Roj~

HS~ ~R3 R4 2 R~4 X

a, R5I
Rl R2 ~ ~. H~
HHO~X

j~ N-RX ~ R4 Or'~TH 3 8 8 wherein Rl, R2, R3, R4, R5 and X are as defined above and R is lower alkyl having 1-S carbon atoms.

As can be seen from the diagram, the Nl substituted quin-azolinone (2) is prepared by reacting a substituted quina-zolinone with an appropriately substituted olefin, such as methyl cinnamate, methyl acrylate, methyl crotonate, acrylonitrile and methyl methacrylate, for example. The particular olefin employed will depend upon the type of substitution desired in the end product. The reaction is carried out in the presence of a basic catalyst such as sodium carbonate, potassium carbonate, potassium fluoride, sodium fluoride, potassium hydroxide, sodium hydroxide, alkali metal alkoxides such as potassium ethoxide, and sodium methoxide, quaternary ammonium hydroxides such as benzyltrimethylammonium hydroxide, quaternary ammonium fluorides such as tetraethylammonium fluoride and tertiary amines such as triethylamine. The reaction temperature employed can vary between -10C and 100C; the preferred reaction temperature is about 65C.

The Nl substituted quinazolinone (2) can be used to pre-pare the other Nl substituted quinazolinones by the routes shown in the diagram. For example, the Nl substituted quinazolinone (2) can be conveniently alkylated with an alkyl iodide such as methyl or ethyl iodide or a benzyl iodide such as o , m-, or E~ ~luorobenzyl, o-, m~, or methylbenzyl and Q-, m-, or p- methoxybenzyl iodide to give the corresponding quaternary salt. The salt in ~urn can be hydrolyzed with an acid such as hydrobromic acid or hydriodic acid, for example, to give the corresponding dihydroxy compound (33. The Nl substituted ~uinazolinone
(2) can be converted directl~ to the corresponding dihydroxy compound (5) by reaction with an acid such as hydrobromic or hydriodic acid. The dihydroxy compounds ORTH-38~

(3 and 5) can then be partially saturated (4 and 6) by reaction with hydrogen in the presence of a catalyst such as platinum, palladi~m, rhodium or nickel. Ammonium formate, boranes and metallic hydrides such as sodium borohydride may also be employed as reagents in the reduction step.

The starting material (1) used in the preparation of the substituted hydroxyquinazolinones wherein the substituents on the benzene ring are in the 6,7-position can be pre-pared by two main routes. For the first, an appropriately substituted alkoxyaniline is converted to the correspond-ing isocyanate. The conversion is carried out with phosgene in a suitable solvent such as, for example, benzene, toluene or xylene. The isocyanate is then con-densed with the appropriate carboxamide to form the cor-responding adduct. The condensation can be carried out either neat or in an inert solvent such as xylene or toluene. It is preferred to carry out the reaction at a temperature between 100-150C. The adduct is then cyclized to form a quinazolinone. Suitable cyclizing agents which can be employed include polyphosphoric acid, polyphosphoric ester and a mixture of phosphorous pent-oxide and methanesulfonic acid. ~he ratio of the cyclizing agent to the adduct may vary between 1:1 and 25:1; however, the preferred ratio is 5:I. The reaction is preferably carried out at a temperature between 100-130C in an inert atmosphere such as nitrogen. In the second route, an appropriately substituted acetophenone is nitrated. After separation of the isomers the substituted o-nitroacetophenone is reduced to the corresponding amine.
This in turn is acylated with an alkylhaloformate to give the corresponding urethane. Cyclization of the urethane so obtained with ammonia gives the corresponding quinazo-linone. Examples of these transformations are illustratedbelow.

~2~

Pharmaceutical compositions containing a compound of the present invention as the active ingredient in in~imate admixture with a pharmaceutical carrier can be prepared accocding to conventional pharmaceutical compounding tech-ni~ues. The carrier may take a wide variety of formsclepending on the for~ of preparation desired for adminis-tration, e.g., intravenous, oral or parenteral. In pre-paring the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like in the case of oral liquid preparations such as, for example, suspen-sions, elixirs and solutions; or carriers such as starches, sugars, diluents, granulating agents, lubri-cants, binders, disintegrating agents and the like in thecase of oral solid preparations such as, for example, powders, caps~lles and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be sugar coated or enteric coated by standard techniques. For parenterals, the carrier will usually comprise sterile water, though other ingredien~s, for example, to aid solubility or for preservatlve pur-poses, may be included. Injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents and the like may be employed. The pharmaceutical compositions will generally con~ain, dosage unit, e.g., tablet, capsule, powder, injection, teaspoon-ful and the like, from about 15 to about 300 mg/kg and preferably fro~ about 30 to about 200 mg/kg of the active ingredient.

The following examples describe the invention in greater particularity and are intended to be a way of illustrating but not limiting the invention.

Example 1 6,7-Dihydroxy-4-methyl-2(1H)quinazolinone-1-(3'-methyl) propionic acid Monohydrobromide Monohydrate A solution of methyl 6,7-dimethoxy-4-methyl-2(1H)quinazo-linone-1-(3'-methyl)propionate (1.0 g, 3~2 mM) in acetic acid (10 ml) and 48% aqueous hydrogen bromide (10 ml) is refluxed for 66 hours. The reaction mixture is cooled. A
green precipitate results which is isolated by filtration, washed with cold ether (20 ml) and dried under vacuum to afford the product (300 mg, 25~), mp 220-222C; ~TMA 1.71-1.95 (d, 3H, 3'-CH3), 3.04 (s, 3H, 4-CH3) 3.18-3.53 (m, lH, -C-CH3), 5.21-5.82 (m, 2H, -CH2-), 7.62 (s, lH, C5-H), 7.79 (s, lH, C8-H); M~ 273.

Example 2 6,7-Dihydroxy-3,4-dimethyl-2(1H)quinazolinonium-l-propionic acid Bromide A solution of methyl 6,7-dimethoxy-3,4-dimethyl-2(1H)-quinazolinonium-l-propionate iodide (1.5 g, 33 mM) in acetic acid (10.5 ml) and 48% aqueous hydrobromic acid (10.5 ml) is refluxed with stirring for 48 hours. The brown reaction mixture is cooled to room temperature and a yellow precipitate is isolated by filtration. After washing with cold ether (25 ml) and drying under vacuum, the product (650 mg, 55~) is isolated.
mp 270-272C; ~TMS 3.22 (s, 3H, 4 CH3), 3.01-3.42 (m, 2H, 2'-CH2), 4.12 (s, 3H, =~CH3), 4.67-5.11 (t, 2H, 2'=CH2), 7.47 (s, lH, C5-H), 7.93 (s, lH, C8-H); M+ 278 (M-80).

Exam~le 3 6,7-Dihvdroxv-4-methyl-2(1H)quina7Olinone-1-(2'-methyl) propionic acid A solution of methyl 6,7-dimethoxy-4-methyl-2(1H)quinazo-linone-1-(2'-methyl)propionate (2.40 g, 7.5 mM), acetic acid (25 ml) and 48% aqueous hydrogen bromide (25 ml) is refl~xed for 48 hours under nitrogen. The reaction mixture is cooled in an ice bath, concentrated in vacuo to half volume and basified to pH 12 with lN sodium hydroxide (25 ml). The reaction is chilled again and acidified with glacial acetic acid to pH 5. A yellow precipitate results which is isolated by filtration, washed with cold ether and dried under vacuum to afford the product. (1.60 g, 7609%);
mp 266-268C; ~TMS 1.38-1.65 (d, 3H, 2'-CH3), 2.99 (s, 3H-H N-4-CH3), 3.10-3.49 (m, lH, -C-), 3.91-5.09 (m, 2H, CH2 C), 7.37 (s, lH, C5-H), 7.72 (s, lH, C8-H); M+ 278.

When in the above procedure methyl 6-methoxy-4-methyl-2(1H)quinazolinone-l-propionate, methyl 7-methoxy-4-methyl-2(1H)quinazolinone-l-propionate, methyl 6-methoxy-2(1H)quinazolinone-l-propionate, methyl 7-~ethoxy-2(1H)-quinazolinone-l-propionate, methyl 6-~ethoxy-4-trifluoro-methyl-2~1H)quinazolinone-l-propionate and methyl 7-methoxy-4-trifluoromethyl-2(1H)quinazolinone-l-propionate are employed in place of methyl 6,7-dimethoxy-4-methyl-2(1H)quinazolinone-1-(2'-methyl)propionate the corres-ponding 6-hydroxy-4-methyl-2(1H)quinaæolinone~l-propionic acid, 7-hydroxy-4-methyl-2(1H)quinazolinone-l-propionic acid, 6-hydroxy-2(1H)quinazolinone-l-propionic acid, 7-3S hydroxy 2(lH)quinazolinone-l-propionate~ 6-hydroxy-4-trifluoromethyl-2(1H)quinaæolinone-l-propionic acid and 7-hydroxy-4-trifluoromethyl-2(1H)quinazolinone-l propionic acid are obtained.

:~2~

Example 4 6,7-Dihydroxy-4--methy1-2(1H)quinazolinone-1-(2'-methyl) propionic acld tripotassium salt monohydrate S A suspension of 6,7 dihydroxy-4-methyl-2(1H)quinazolinone-1-(2'-methyl)propionic acid (1.5 9, 5.39 mM) in methanol (100 ml) is treated with 1.0~ methanolic ~OH (16.17 ml, 16.1 mM) with good stirring ~nder nitrogen. The resulting dark solution is filtered under nitrogen and concentrated in vacuo to a yellow solid. The solid is triturated with acetone (40 ml) and isolated by filtrationO After washing with ether (20 ml), the solid is dried in a dessicator under vacuum for 16 hours at room temperature to afford 6,7-dihydroxy-4-methyl-2(1H)quinazolinone-1-(2'-methyl) propionic acid tripotassium salt monohydrate (2.2 9, 100%); mp >300C.

ExamE~
6,7-Dihydroxy-4-methyl-1-(3'-phenylpropyl)-2(_H ~ -linone Monohydrate A mixture of 6,7-dimethoxy-4-methyl-1-(3' phenylpropyl)-2(1H)quinazolinone (1.25 g, 3.6 mM) and 43% aqueous hydrogen bromide (10 ml) in glacial acetic acid (10 ml) is refl~xed with stirring for 24 hours. After cooling to room temperature, the reaction mix~ure is quenched on ice ~100 9). A yellow-brown solid deposits which is isolated, washed with water (2x20 ml) and then with ether (3x40 ml).
After drying in air, 1.21 9 (100~) of the product is obtained.
mp >275C dec.; ~ TMS 2.00-2.70 (m, 2H, -CH~-), 2.75-3.30 (m, 2H, -CH~-0), 3.00 (s, 3Hr CH3), 4.30-5000 (t, 2H, 35 -CH,N), 7.07 and 7.65 (2s, 2H, C5H, C~H), 7.25 (s, 5H,0-);
~I+ 310.

.

4~

~hen in the above procedure 6,7-dimethoxy-4-methyl-2(1H)-quinazolinone-1-(2-methanesulfonyl)ethane, 6,7-dimethoxy-4-methyl-2(1H)quinazolinone-1-(2-benzoyl)ethane, and 6,7-dimethoxy-~-methyl-2(lH)quinazolinone-l-2-(2~-pyridyl)-ethane, are employed in place of 6,7-dimethoxy-4-methyl-1-(3-phenylpropyl)-2(1H)quinazolinone the corresponding 6,7-dihydroxy-4-methyl-.1-(2-methanesulfonyl)ethane-2(lH)-quinazolinone monohydrate, 6,7-dihydroxy-4-methyl-1-2(benzoyl)ethane-2(1H)quinazolinone monohydrate, and 6,7-dihydroxy-4-methyl-1-2(2'-pyridyl)ethane-2(1H)quinazoli-none monohydrate are obtained.

When in the above procedure 6,7-dimethoxy-4-methyl-2(1H)-quinazolinone-l-propionaldehyde, 6,7-dimethoxy-4-methyl-2(1H)quinazolinone-l-propionitrile and methyl 6,7-dimethoxy-4-methyl-2(1H)quinazolinone-l-(l-phenyl)propio-nate are employed in place of 6,7-dimethoxy-~-methyl-1-(3-phenylpropyl)-2(lH)quinazolinone the corresponding 6,7-~ dihydroxy-4-methyl-2(lH)quinazolinone-l-propionaldehyde, - -~ 20 6,7-dihydroxy-4-methyl-2(1H)quinazolinone-l-propionic acid and 6,7-dihydroxy-4-methyl-2(1H)quinazolinone~l-(l-phenyl) propionic acid are obtained.

The following compounds are prepared by the procedure of Examples 3, 4 or S using an appropriately substi.t~ted quinazolinone as the starting materialO

R6O ~ ~

wherein R6 is potassium or hydrogen and R2 is as de~ined.

R2 Hydrobromide Salt Free Acid Tripotassium Salt _ _p/Yield % mp/Yield ~ mp/Yield %
H 231~232C/57.8 CH~ 257-259C/82.5 >300C/96.9 CF3 125-130C/22.2 >310C/76.6 ethyl 308-310C/84~5 305-306C/73.3 propyl 264-266C/42.8 328-329C/71.4 310-312C/97.2 isopropyl 310-312C/73.3 Dec.>300C/74.0 n-pentyl 222-224C/79.2 275-277C/72.3 n-hexyl 242-246C/64.3 Dec. 220C/68.2 n-heptyl 248-250C/91.6 n-octyl 238-240C/55.1 302~304C/80.0 n-decyl 164-166C/71.6 259-261C/100.0 CH2-CH2 276-278C/88.0 228-230C/8.9 fH2 CH~cH_ 276-278C/74.6 298-300C/91.5 CH2-CH~
CH -CH
1 ~ 2~ CH-CH2~ 262-264C/79.0 Example 6 Ethyl 6,7-dihydroxy-4-methyl-2(1H)quinazolinone-1-propionate A suspension of 6,7-dihydroxy-4-methyl-211H)quina~olinone -l-propionic acid (2.0 g, 6.5 mM) in absolute ethanol (35 ml) containing methanesulfonic acid (1.0 ml) is refluxed with stirring for 3 days. The reaction mixture is cooled to room temperature and quenched on ice (200 g3.
A yellow-green precipitate forms which is isolated, washed with water, acetone, and ether and then dried in vacuo to afford the product. (1.75 g, 92.2%); mp >308C (dec.);
IOl ~TTFA 1.35-1.60 (t, 3H, CH2CH3), 2.g5-3.30 (m, 2H, CH~C-),
3.10 (s, 3H, CH3), 4.20-4.60 (q, 2H, CH2-O), 4.65-5.00 (t, 2H, CH2-N), 7.35 (s, lH, C5-H), 7.75 (s, lH, C8-H); M+ 292.

g6~

Example ?
-6,7-Dihydroxy-3,4-dimethyl-3,4-dihydro-2(1H)~uinazolinone -l-propion_ acid A solution of the quaternary salt 6,7-dihydroxy-3,4-di-methyl-2(lH)quinazolinonium-l-propionic acid bro~ide (1 meq) in glacial acetic acid (15 ml) is treated with 5~ Pd/C (0.1 9) and the reaction mixture is hydrogenated at 45 psi for 12 hours. The catalyst is filtered and the mother liquor is poured into water (100 ml). The precipi-tate of 6,7-dihydroxy-3,4-di~ethyl-3,4-dihydro 2(1H)quin-azolinone-l-propionic acid is filtered, washed with water and dried _ vacuo.

Example 8 6,7-Dlhydroxy-3,4-dihy~ro-4-methyl-2(lH)quinazolinone-l-propionic acid monohydrate A slurry of 6,7-dihydroxy-4-methyl-2(1H)quinazolinone-1-20 propionic acid monohydrate (5.0 g, 17.7 mM) in methanol (270 ml) is treated with Pd/C (10%, 2.5 9) and the mixture hydrogenated at 45 psi for 16 hours. Filtration, removal of the solvent in vacuo and titration of the residue with acetone gives the product as a tan solid (4.3 g, 91.4%);
25 mp 202-204C; ~TTMAs 6.86 (s, lH, 5-H), 6.83 (s, lH, 8-H),
4.78 (d, lH, J=7.0 Hz, 4-H), 4.36 (t, 2HI J=10 Hz, 2'-H), 3.03 (t, 2H, J=10 H~ H), 1.55 (d, 3H, J=7 Hz, 4-CH3);
30 M+ 266.

Example 9 6,7-Dihydroxy~3-benzyl 4-methyl-2(1H)~uinaz_linonium-l-~ropionic ac d bromide A solution of methyl 6,7-dimethoxy-4-methyl-2(1H) quinazolinone-l-propionate (10 9) in acetone (100 ml) is treated with benzyl bromide (10 eq) and the solution aged overnight at room temperature. The resulting crystalline precipitate is isolated and dried in vacuo. The crude quaternary salt is then dissolved in a mixture of glacial acetic acid (70 ml) and 48% aqueous Hsr (70 ml) and the reaction mixture refluxed Wit}l stirring for three days.
Upon cooling to room temperature 6,7-dihydroxy-3-benzyl-4-methyl-2(1H)quinazolinonium-l-propionic acid bromide is isolated as a crystalline precipitate.

Identical conditions are utilized employing ~-fluorobenzyl bromide and E-chlorobenzyl bromide to give the correspond-ing substituted benzyl quaternary salts.

Example 10 15 6,7-Dih~drox~4-norbornylmethyl-2(lH~quinazolinone-1-propionic acicl hydrobrom _ e A mixture of methyl 6,7-dimethoxy-4-norbornylmethyl-2(1H)-quinazolinone-l-propionate (5 g), 48% aqueous HBr (40 ml) and glacial acetic acid (40 ml) is refluxed with stirring for three days. The solu~ion is then cooled and the resulting gold precipitate isolated by filtration, washed with acetone (25 ml) and dried in vacuo to afford the title compound.
When in the above procedure methyl 6,7-dimethoxy-5-amino-4-methyl-2(lH)quinazolinone-l-proplonate and methyl 6,7-dimethoxy-5-nitro-4-methyl-2(1H~uinazolinone-l-propionate are employed in place of methyl 6,7-dimethoxy-4-nor-bornylmethyl-2(lH)quinazolinone-l-propionate, the corres-ponding hydrobromides 6,7-dihydroxy-5-amino-4-methyl-2(1H)quinazolinone-l-propionic acid dihydrobromide and 6,7~dimethoxy-5-nitro-4-methyl-2(1H)quinazolinone-l-propionic acid hydrobromide are obtained. The propionate 3S starting materials are prepared according to the procedure outlined in Example G.

ORTH-38~

~2~

Exa~ple 11 6,7-Dih~_roxy-4-methyl-2(1H)quinazolinone-l-propionic acid monopotassium salt
5 A suspension of 6,7-dihydroxy-4-methyl-2(1H)quina2Olinone-l-propionic acid (9.97 g, 37.10 mM) in methanol (30 ml) under nitrogen, is treated with lN KOH in methanol (37.10 ml, 37.10 mM). The resulting yellow slurry is stirred at room temperature, under nitrogen, for 22 hours.
The reaction mixture is cooled in an ice-water bath and filtered. The resulting yellow solid is washed with cold methanol (3x17 ml) and dried in vacuo at 120C for 336 hours (14 days). The product (10.41 9) is obtained as a yellow solid, mp = 303-305C.
Example 12
6,7-Dihydroxy-4-methyl-~(lH)quinazolinone-l-~ropionic acid dipotassium salt 20 A suspensiorl of 6,7-dihydroxy-4-methyl-2(1H)quinazolinone-1-propionic acid (45.0 g 167.47 mM) in methanol (600 ml) is treated with lN KOH in methanol (334~94 ml, 334.94 mM) at room temperature under nitrogen; a large a~ount of yellow solid is present after addition of the KOH. Addi-tional methanol (200 ml) is added. Water is then added until the solid dissolves. The total amount of water added is 300 ml. The reaction mixture is then stirred at room temperature, under nitrogen for 30 minutes. The slightly cloudy solution is then filtered and concentrated to dryness in vacuo to give a yellowish-brown semi-solid.
This is triturated with acetone (300 ml) and the resulting yellow solid filtered and dried to afford the dipotassium salt (54.26 g, mp >325C).

~22~

6,7-Dihydroxy-4-methyl-2(lH)quinazolinone-l-propionic acid monoarginine salt monohydrate A mixture of 6,7-dihydroxy-4-methyl-2(1H)quinazolinone-l-propionic acid (4.0 9, 14.6 mM) and L-arginine (2.34 9, 14.6 mM) in water (150 ml) is aged at room temperature for 3 ho~rs. After 15 minutes the initial solution clears and then a yellow precipitate begins ~o form. ~fter 3 hours, this precipitate is isolated, washed with wa~er (15 ml), acetone (20 ml), and then ether (2 x 20 ml). The precipi-tate is dried in vacuo at 60C. for 3 hours to give the -amino acid salt (5.81 9, 93.8%).

Example 14 6,7-Dihydrox~-4 methyl-2(1H)quinazolinone-l-propionic acid N-methylglucamine salt A mixture of 6,7-dihydroxy-4-methyl-2(1H)quinazolinone-l-propionic acid (0.79 9, 3 mM), meglumine (0.59 g, 3 mM), methanol (40 ml) and water (4 ml) is aged at ambient temperature overnight. The resulting slurry is filtered and the precipitate washed with ether (2 x 20 ml). After drying in air for 3 hours, the amine salt is isolated as a yellow solid, (0.88 9, 62.51%, mp = dec. 197-8C).

The salts from monoethanolamine, piperazine, N-methylpi-perazine and morpholine are prepared in a similar fashion.

Example 15 6,7-Dihydroxy~4~methyl-2(1H)quinaxolinone-l-pro~ionic acid mono~2-methyl-~2-amino-1,3-propandiol) salt monohydrate A suspension of 6,7-dihydroxy-4 methyl-2(1H)quinazolinone-l-propionic acid (1.0 9, 3.6 mM) in methanol (40 ml) and ~2Z~

water (10 ml) is treated with mono(2-methyl-2-amino-1,3-propandiol) (0.38 9, 3.6 mM) and the mixture aged at ambient temperature for 16 hours. The resulting pale-yellow precipitate is isolated, washed with methanol (10 ml) and ether (2 x 10 ml). After drying in vacuo for 6 hours at 60C, the amine salt (1.18 g, 85.5%) is isolated, mp = 212-13C.

Example 16 6,7-Dihyd~oxy-4-methyl-2(1H)quinazolinone-l-propionic aci_ mono(l-amino-2,3-propandiol) salt hemihydrate A mixture of 6,7-dihydroxy-4-methyl-2(1H)quinazolinone-l-propionic acid (0.84 g, 3 mM), mono (l-amino-2,3-propan-diol) (0.27 g, 3 mM), methanol (40 ml) and water (10 ml) is aged overnight at room temperature. The resulting precipitate is isolated and washed with methanol (10 ml) and ether (1 x 20 ml). After drying under a stream of nitrogen for 3 hours, the amine salt (0.94 g, 84.73) is obtained.

Example 175,6-Dihydroxy-4-methyl-2(1H)~uinazolinone-l-propionic acid Monohydroiodide Methyl 5,6-dimethoxy-4-methyl-2(1H)quinazolinone-l-propionate (1.173g, 3.83mM) is treated with 50% aq HI
(13 ml) at room temperature to give a clear orange solution which is refluxed under nitrogen for 11 hr. and then allowed to stir at room temperature overnight. The orange crystalline solid which precipitates is collected by filtration, washed with acetone and dried to give the product; yield 0.972 g, (65%), mp. 240-241C(d) IR
(KBr)~, 3.23 (broad, OH), 5.78 (C=O).

When in the above procedure methyl 5,6-dimethoxy-4-tri-Eluoromethyl-2~1H)quinazolinone-l-propionate, methyl 5,6-dimethoxy-~-isopropyl-2(1H)quinazolinone-l-propionate methyl 4-cyclopentyl-5,6-dimethoxy-2(1H)quinazolinone l-propionate, and methyl 4-cyclohexylmethyl-5,6-dimethoxy-2(1H)quinazolinone-1-propionate are employed in place of methyl 5,6-dimethoxy-4-methyl-2(1H)quinazolinone-l-pro-pionate the correspondiny 5,6-dihydroxy-4-trifluoromethyl-2(1H)quinazolinone-l-propionic acid monohydroiodide, 5,6-dihydroxy-4-isopropyl-2(1H)quinazolinone-l-propionic acid monohydroiodide, 4-cyclopentyl-5,6-dihydroxy-2(1H)quina-zolinone-l-propionic acid monohydroiodide and ~-cyclo-hexylmethyl-5,6-dihydroxy-2(lH)quinazolinone-l-propionic acid monohydroiodide are obtained. The ester starting materials are prepared accordiny to the method outlined in Example G.

Example 18 6,7-Dihydroxy-4-methyl-2(1H)quinazolinone-l-propionic acid Monoh~drate A suspension of methyl 6,7-dimethoxy-4-methyl-2(1H)quina-zolinone-l-propionate (1.53 g, 5 mM), acetic acid (20 ; ml) and 48% aqueous HBr (15 ml) is refluxed for 120 hours under nitrogen. The solvent is removed ln vacuo to yield a greenish hydrobromide salt Iyield 1.5 9, 88.2%); mp 292-295C. A solution o~ the salt in methanol (5 ml) is treated with saturated aqueous NaHCO3 until the pH is neutral. The precipitated free base is collected by filtration and washed with acetone to obtain the product ; (yield 1.0 g, 76.9%) as a pale green solid, mp 308-310C;
NMR: ~TMS 7.80 (s, lH, 5-H), 7.46 (s, lH, 8-H), ~.66-5.08 (m, 2H, 2'-H), 3.13 (m, 5H, l'-H, 4-CH31 M+ 264.

.

~19--The various other substituted mono- and dihydroxy-2(1H)-quinazolinones encompassed by the present invention can be prepared b~ any of the above methods using an appropriate-ly substituted mono- or dialkoxy-2(1H)~uinazolinone pre-S pared according to the examples utilizing the variousstarting materials described below.

The biological activity of the novel quinazolinones was determined according to the method of Goldberg, L.I., Sonneville, P. F. and McNay, J. L. (1968). An investiga-tion of the structural requirements for dopamine-like renal vasodilation; phenethylamines and apomorphine, J.
Pharmacol. Exp. Ther. 163.

Adult mongrel dogs are anesthetized and surgically pre-pared for electromagnetic measurements of renal artery blood flow. A carotid artery is cannulated for measuring arterial blood pressure and drugs are administered intra-venously. Heart rate is monitored by a cardiotachometer.
~0 Renal vascular resistance is calculated as the ratio of mean arterial blood pressure/renal artery blood flow.
Dopamine is infused intravenously at 3 ~g/kg/min for ten minutes (1 ~l/min) to determine responsiveness of each dog to renal dopamine receptor stimulation. Cumulative dose-response data are obtained by infusing the test drug atprogressively increasing (usually three fold) infusion rates, each dose being infused five ~inutes. The maximum percent increase from pre-drug control in renal artery blood flow (or decrease in renal vascular resistance) is quantitated for each infusion dose.

6~

Preparation of Startin~ Materials Example A
3,4-Dimethoxyphenylisocyanate s Phosgene (4 eq) is bubbled at a moderate rate into a 3-neck flask containing a solution of 3,4-dimethoxyaniline (1 eq.), in benzene (2 liters). The flask is cooled in an ice bath for 15 minutes and then the solution is refluxed for 1 3/4 hours while excess phosgene is added. The reac-tion mixture is then refluxed overnight and the solvent removed under vacuum. Acetone is added and the solvent is again removed under vacu~m leaving a dark brown oily resi-due which is distilled at 132-134C/0.6 mm. Yield: 22.5 g.

~ `
N-(3,4-Dimethox~henyl)-N'-propionylurea A mixture of 3,4-dimethoxyphenylisocyanate (26.0 g, 145 mM) and propionamide (10.61 g, 145 mM) is heated at 160-165C for 1 1/2 hours. A homogeneous pale yellow solution forms which after 15 minutes solidifies. The heating is discontinued and the flask is allowed to cool slowly. The mixture is triturated with acetone and this resulting white solid is filtered and dried. Yield:
32.45 9, mp 193-197C.

Example C
6,7-Dimethox~-4-ethyl-2(1H)~uinazolinone A suspension of N-(3,4 dimethoxyphenyl)-N'-propionylurea (32~45 9, 128 mM) in polyphosphoric acid (375.12 g, 1109 mM) is heated at 130-135C under nitrogen with vigorous stirring for 3.5 hours. The mixture is then poured onto 500 g ice H2O and stirred. The solution is brought to pH 5.5 with concentra~ed NH40H and allowed to stand at room temperature overnight. ~ brown precipitate ~2~

forms. The resultir,g solid is filtered and dried to yield
7.40 g of a white solid. This filtrate is extracted with CHCl3 (5x 250 ml), the organic extract is dried (MgS04) and the solvent removed in vacuo to give a tan solid. The solid is triturated with acetone and filtered to give a tan solid (4.98 g). A sample is slurried in water and redried for additional purification, m.p. 263-265C.
10 ~TMS 7 50 (s, lH, 5-H), 7.23 (s, lH, 8-H), 4.30 (s, 3H, 6 or 7-OCH3) 4.17 (s, 3H, 6 or 7-OCH3), 3.50 (q, 2H, J=8.0Hz, CH~CH3), 1.70 (t, 3H, J-8.0Hz, CH~3).

Tabulated below are selected examples of 2(1H)~uinazoli-nones prepared by the route described above~

ORTH~388 R2 M.P./C % Yield H 247-248 67.5 CH3 269-271 65.0 CF3 280-282 46.3 propyl 208-210 53.8 isopropyl 233-240 86.0 n-pentyl 152-154 21.9 -CH2-CH 199-202 14.4 ~ H3 n-hexyl 120-123 8.0 n-heptyl 184-186 78.2 n-octyl 130-132 24.4 n-decyl 166~167 37.4 -CH2 ~ 262-264 79.0 fH~-7H2 253-255 12.6 CH~-ÇH2 C\2/ H
CH~

~ CH2- 298-302 16.6 Example D
3,4-Dimethoxy-6-nitroacetophenone 3,4-Dimethoxyacetophenone (1.8 eq) is added during 0.5 hour to nitric acid (18 eq), at 0O After a further 1 hour at 20C., the dark brown solution is poured onto ice water. The crude product is collected by filtration.
: Recrystallization from ethyl alcohol affords the purified product, mp = 124-126C; ~CDC13 2.50 (s, 3H, CH3), 4.00 (s, 6H, OCH3's), 6.80, 7.59 (2s, lH ea., C2H, C5H).

.

Example E
6-Amino-3,4-dimet_oxyacetophenone A slurry of 1 equivalent of 3,4-dimethoxy-6-nitroaceto-phenone in methanol is treated with Pd/C (10%) and the mixture is hydrogenated at 45 psi for 24 hours. The resi-due after filtration and removal of solvent is crystal-lized from ethyl alcohol to afford purified product, mp =
98-100C; ~TMS 3 2.50 (s, 3H, CH3), 3.80-3.85 12s, 3H ea., OCH3); 6.05, 7.05 (2s, lH ea., C2H, C5H).

Example F
2-(N-Carbethoxyamino)-4,5-dimethoxyacetophenone Ethyl chloroformate (1 eq) is added cautiously with stir-ring to 6-amino-3,4-dimethoxyacetophenone (0.3 eq) at room temperature. The dark brown reaction mixture is stirred at room temperature for 1/2 hour. Aqueous sodium hydrox-ide is added and the reaction mixture stirred at room temperature for an additional hour. The reaction mixture is extracted with chloroform. Removal of chloroform gives an oily residue. Recrystallization from ether affords the product, mp = 97-99C; ~TDsc 3 1.10-1.50 (t, 3H, CH3), 2.60 (s, 3H, CH3), 3.~5 and 3.95 (2s, 3H ea., OCH3's), 4.0~4.4 (q, 2H, CH2), 7.15 and 8.20 (2s, lH ea., C2H, C5H).

General Preparation of me~hyl 2(1~)quinazolinone-1-propionates ~ N ~

~2~6~

An appropriately substituted 2(1H)quinazolinone (S g) is placed in a mixture of methanol (75 mol), chloroform (100 ml), methyl acrylate (125 ml) and excess Triton a (40% methanol) and the mixture is refluxed with stirring for 4-16 hours. The solution is then cooled and after evaporation of the solvent, the ester is obtained by chromatography on silica gel.

The following compounds are made by the above general procedure:
R2 M.P/C

CH3 155~157 ethyl 132-134 propyl 120-122 isopropyl 112-114 n-pentyl oil n-hexyl 122-124 n-heptyl 107-110 n-octyl 100-104 n-decyl oil fH 2-CH2 140-142 CH2- ~
CH2-~H2 103-105 \ /
CH~
f 2 2 CH-CH2- 92-95 When in the above procedure 6-methoxy-4-methyl-2(1H)quina-zolinone, 4-methyl-7-methoxy-2(1H)quinazolinone, 6-methoxy-2(lH)quinazolinone, 7~methoxy-2(lH3quinazolinone, 6 methoxy-4-trifluoromethyl-2(1H)quinazolinone and .

~z~

7-methoxy-4-trifluoromethyl-2(1H)quinazolinone are employed as the starting materials, the corresponding 1-propionic acid esters are ob~ained.

S When in the above procedure 3,4-dihydro-5,6-dimethoxy-4-methyl-2(1H)quinazolinone, 5,6-dimethoxy-4-methyl-2(1H)-quinazolinone, 5,6-dimethoxy-4-trifluoromethyl-2(1H)-quin-azolinone are employed as the substituted quinazolinone the corresponding l-propionic acid esters are obtained.
Example H
6,7-Dimethoxy-4-methyl-2(lH)quinazolinone-1-(2-methane-sulfonyl)ethane A solution of 6,7-dimethoxy-4-methyl-2(1H)quinazolinone (10 g) in chloroform (100 ml), methanol (100 ml) and methylvinyl sulfone (40 eq) is treated with Triton B
(benzyltrimethylammonium hydroxide, 40% in methanol, 1.1 eq) and the solution refluxed, with stirring, for 24 hours. The solution is then cooled to room temperature and the solvent removed by concentration in vacuo. The residue is chromatographed on silica gel to afford puri-fied 6,7-dimethoxy-4-methyl-2(1H)quinazolinone-1-(2-methanesulfonyl) ethane.
Exam~e I
6,7-Dimethoxy-4-methyl-2(1H)~uina~olinone-1-(2-benzoyl) ethane A solution of 6,7-dimethoxy-6-methyl-2(1H3quinazolinone (10 y) in chloroform (100 ml), methanol 1100 ml) and phenylvinyl ketone (40 eq) is treated with Triton B (40%
in methanol, 1.1 eq~ and the solution refluxed with stir-ring for 24 hours. Af~er cooling to room temperature, the solvent is removed in vacuo and the residue chromato-graphed on silica gelO Purified 6,7-dimethoxy-4-methyl-2(1H)quinazolinone-1-(2-benzoyl) ethane is obtained.

* Trademark 46~3 Example J
6,7-Dimethoxy-4-methyl-2(lH)quinazolinone-1-[2-(2'-~ )ethane]

A solution of 6,7-dimethoxy-4-methyl-2(1H)quinazolinone (10 g) in chloroform (100 ml), methanol (100 ml and 2-vinylpyridine (25 eq) is treated with Triton B (40~ in methanol, 1.1 eq), and the solution refluxed with stirring for 24 hours. The resulting solution is cooled to roo~
temperature and the solvent removed by concentration in vacuo. The residue is chromatographed on silica gel to give purified 6,7-dimethoxy-4-methyl-2(1H)quinazolinone-l-[2-(2'-pyridyl)ethane].

When in the above procedure 4-vinylpyridine is employed in place of 2-vinylpyridine the corresponding 4'-pyridyl derivative is obtainedO

Example K
6,7-Dimethoxy-4-methyl-2(1H)quinazolinone-l-propionaldehy~

A solution of 6,7-dimethoxy-4-methyl-2(1H)qulnazolinone (10 g) in methanol (100 ml), chloroform (100 ml) and acro-lein (40 eq) is treated with Triton B (40% in methanol, 1.1 eq). The resulting mixture is concentrated in vacuo and the residue is chromatographed on silica gel to afford purified 6,7-dimethoxy-4-methyl-2 (lH~quinazolinone-l-propionaldehyde.

Exam~le L
6,7-Dimethoxv-4-methYl-2(lH)quinazolinon~ propionitrile A solution of 6,7-dimethoxy-4-methyl-2(1H)quinazolinone (10 g) in chloroform (100 ml), methanol (100 ml) and acrylonitrile (excess) is treated with Triton B (40% in ` methanol, x's). The solution is refluxed with stirring for 24 hours. The resulting solution is cooled to room ~Z~ 8 temperature and the solvent is removed by evaporation _ vacuo. The resulting residue is chromatographed on silica gel to give purified 6,7-dimethoxy-4-methyl-2(1H) quinazolinone-l-propionitrile.

Methyl 6,7-dimethoxy-4-methyl-2(1H)qulnazolinone-l-(l-phenyl)_propionate A solution of 6,7-dimethoxy-4-methyl-2(1H)quinazolinone (10 9) in chloroform (100 ml), methanol (100 ml) anc3 methyl -phenylacrylate (excess) is treated with Triton B (40% in methanol, 1.1 eq) and the resulting solution refluxed with stirring for 24 hours. After cooling to room temperature, the solvent is removed in vacuo and the residue purified by chromatography on silica gel to give purified methyl 6,7-dimethoxy-4-methyl-2(lH)quinazolinone-l-(l-phenyl)propionate.

When in the above procedure methyl (2,4~difluorophenyl) acrylate, methyl (4-chlorophenyl)acrylate and methyl (4-methoxyphenyl acrylate are employed in place of methyl a-phenylacrylate, the corresponding quinazolinones methyl 6,7-dimethoxy-4-methyl-2(1H)quinazolinone-1-~1-(2,4-difluorophenyl)propionate]; methyl 6l7-dimethoxy-4-~ethyl-2(1H)quinazolinone-1-[1-(4-chlorophenyl) propionate~; and methyl 6,7-dimethoxy-4-methyl-2(1H)quinazolinone-1-[1-(4-methoxyphenyl) propiona~e] are obtained.

Exam~le N
Methyl 6,7-dimethoxy-4-methyl-2(1H)~Llnazollnone-1-(2-~henyl pro~ nate) A solution of 6,7-dimethoxy-4-methyl-2(1H)quinazolinone 3S (10 9) in chloroform tlOO ml), methanol (100 ml), and methyl cinnamate (excess) is treated with Triton B (50% in methanol, 1.1 eq) and the resulting solution refluxed with ~2~46~3 stirring for 24 hours. The solution is concentrated in vacuo to remove the solvent and the residue is purified by chromatography on silica gel. In this manner, purified methyl 6,7-dimethoxy-~-methyl-2(1H)quinazolinone-1-(2-phenyl propionate) is obtained.

When in the above procedure methyl 2,4-difluorocinnamate, methyl 4-chlorocinnamate and methyl 4-methoxycinnamate are employed in place of methyl cinnamate, the corresponding quinazolinones methyl 6,7-dimethoxy~4-methyl-2(lH)quinazo-linone-1-[2-(2,4-difluorophenyl)propionate]; methyl 6,7-dimethoxy-4-methyl-2-(lH)quinazolinone-1-[2-(4-chloro-phenyl) propionate] and methyl 6,7-dimethoxy-4-methyl-2(lH)quinazolinone-1-[2-(4-methoxyphenyl)propionate] are obtained.

Example O
6,7-Dimethoxy-4-(2-norbornylmethyl)-2(1H)quinazolinone A solution of norbornyl-2-acetic acid (25.0 gl 0.16 m) in benzene (SO ml) is treated with thionyl chloride (75 ml) and the mixture refluxed with stirring ~or 12 hours. The volatiles are removed on a rotary evaporator at about 50C. The resulting acid chloride is dissolved in tetrahydrofuran (150 ml) and then aqueous concentrated ammonia (200 ml) i5 slowly introduced with stirring. A
precipitate forms during the subsequent 30 minute aging period. It is isolated by filtration and washed well with cold water. After drying, 15.3 9 (62.5%), mp = 1~4-6C, of norbornyl-2-acetamide are ob~ained.

A mixture of 3,4-dimethoxyphenylisocyanate (8.95 9, O.OS m) and norbornyl-2-acetamide (6.12 9, 0.04 m) is fused under nitrogen at 130-140C with stirring for one hour. A~ter cooling, acetone tlOO ml) is introduced and the mixture broken-up manually. A~ter one hour aging at room temperature, the precipitate is isolated and dried in vacuo. A sol~tion of the adduct (9.0 g, 0.027 m) in polyphosphoric acid (200 g) is heated at 130-140C for three hours wlth stirring. After cooling, the reaction mixture is quenched on ice (1500 9) and stirred well.
This pale green solution is brought to pH~ 8.0 with concentrated ammonia. The resulting precipitate is isolated, washed with distilled water (2x50 ml) and dried to yield 6,7-dimethoxy-4-(2-norbornylmethyl)-2-(lH)-quinazoline as a tan solid. After recrystallization from 95% ethanol, pale yellow crystals are obtained, 2.0 g, M.P. 231-2C.

Example P
Methyl 6,7-dimethoxy-4-methyl-2(lH)quinazolinone-1-(3'-m_ b ~ ~n~e Triton B (26.0 ml, 40~ in methanol) is added as a slow stream with stirring to a solution of 6,7-dimethoxy-4-methyl-2(1H)quinazolinone (20.0 g, 91 mM) in methyl 20 crotonate t90.0 9, 900 mM); methanol (80 ml), and chloroform (126 ml) precooled to 0C. The reaction is stirred at reflux for 18 hours. The reaction mixture is then cooled to room temperature and the suspension is isolated by filtration. The filtrate is concentrated in vacuo to give a fluffy solid which is chromatographed on *
SilicAR CC-7 (125 9) prepared in 1:1 C~2Cl2/ethyl acetate.
Elution with 5-20% methanol/CH2C12 aEords the prod~ct as an orange solid (560 mg, 1.9~); mp 55-56C.

Exam~le Q
Methyl 6,7-dimethoxy-4-methyl-2(1H)quinazolinone-l-(2'-methyl)propionate Triton B (26.0 ml, 40% in methanol) is added as a slow stream with stirring to a solution of 6,7-dimethoxy-4-methyl-2(1H)quinazolinone (20.0 g, 91 mM) in methyl methacrylate (206 ml), methanol (79 ml), and chloroform * Trademark (127.5 ml) precooled to 0C. The reaction is stirred at room temperature for 1~ hours and then heated at 50C for 66 hours. The suspension is cooled in an ice bath and the resulting precipitate is isolated by filtration. Water ~75 ml) is added to the filtrate and this solution is extracted with methylene chloride (4x100 ml). The extract is dried (MgSO4), filtered and concentrated in vacuo to give a reddish oil which is chromatographed on SilicAR CC-7 prepared in ethyl acetate. Elution with 5-10% ethyl acetate/ethanol gives an oil. Trituration of this oil with cold ethyl acetate/ether (1:1) deposits white crystals which àre filtered, washed with ether ~25 ml), and dried in vacuo to afford methyl 6,7-dimethoxy-4-methyl-2(1~)-quinazolinone-1-(2'-methyl)propionate.
1~
Example R
Methyl 6,7-dimethoxy-4-norbornylmethyl-2(1H)quinazolinone-1-(2l-m~ElcLLb3ca~L~

A solution of 6,7-dimethoxy-4-norbornylmethyl-2(1E~)quin-azolinone (10 g) in chloroform (50 ml), methan~l (50 ml) and methylacrylate (50 ml) is treated with Triton B
(benzyltrimethylammonium hydroxide, 40% in methanol, 20 ml, excess) and the reaction is refluxed with stirring for 24 hours. After work-up and purification via chroma-tography, the purified product is obtained.

Example S
Methyl 6,7-dimethoxy-3,4-dihydro-3,4-dimethyl-2[1H) ~uinazolinone l-propionate A solution of methyl 6,7-dimethoxy-3,4-dimethyl-2(lH)quin-azolinonium-l-propionate bromide (1 eq) in ethanol (700 ml) is treated with 10 9 10~ Pd/Co The mixture is hydrogenated at ~45 psi for 16 hours until uptake ceases.
The solution is filtered free of catalys~ and ~he filtrate is concentrated in vacuo. The resulting solid is recrystallized from acetone to give a 60-70~ yield of purified methyl-6,7-dimethoxy-3,4-dihydro-3,4-dimethyl-2(lH)quinazolinone-l-propionate.

S ~
6,7-Dimethoxy--5-nitro-4-methyl-2(1H)quinazolinone One equivalent of 6,7-dimethoxy-4-methyl-2(1H)quinazoli-none is added during 3/4 hr. to a mixture (5:1) of 6 equi-valents of concentrated nitric acid (70%) and concentratedH2SO4 at 0 ~ 3C. After one hour at the same temperature the solution is poured onto crushed ice (1000 ml). ~he crude product is collected by filtration, digested with boiling alcohol and the suspension is filtered. Crystal-lization from ethyl alcohol affords 6,7-dimethoxy-5-nitro-4-methyl-2(1H)quinazolinone.

Example U
6,7-Dimethoxy-5-amino-4-methyl-2(1H)quinazolinone A solution of 13 equivalents of FeS04~7H20 in water (6 parts) is heated to 95C. A slurry of 1 equivalent of 6,7-dimethoxy-5-nitro-4-methyl-2(1H)quinazolinone in water (800 ml) at 80C. is added and the resulting yellow mixture is heated at 98-100C. for 15 minutes. Ammonium hydroxide (13 eq) is added to the mixture dropwise over a 15 minute period, maintaining the temperature at 98-100C.
The resulting black reaction mixture is stirred at 98-100C. for 30 minutes, ~he hot mixture is filtered and the insoluble black residue is washed with hot water. The brownish filtrate is extracted with chloroform. The solvent is removed in vacuo to give a dark brown semi~
solid crude product, which is chromatographed on a silica gel column. Recrystallization of the crude product from ethyl alcohol affords purified product.

Example V
6,7-Dimethoxy-3,4-dimethyl-2(lH)quinazolinonium propionic acid methyl_ester Iodide Hemihydrate A large excess of CH3I (20 ml) is added to a solution of methyl 6,7-dimethoxy-4-methyl-2(1H)quinazolinone propionate (2.0 g, 6.53 mM) in acetone (300 ml) and the mixture is refluxed for 3 days. Removal of the solvent in vacuo and subsequent trituration with ether yields a dark brownish solid (2.4 9). Crystallization from isopropyl alcohol and then from methanol affords the product as a yellow solid;
yield 1.2 g (41.3%).

The starting materials for those compounds wherein the lS hydroxyl groups on the aromatic ring are in the 5-, 6- or 7-positions are prepared according to the following examples.

Example W
2-Hydroxy-3-methoxybenzaldehyde-2-benze_esulfonate A slurry of 3-methoxysalicylaldehyde (45.6 g, 299 mM) in NaOH (138 ml, 15% aqueous solution) is treated with benzenesulfonyl chloride (66 g, 373 mM) and the mixture vigorously stirred for 1 hour. The reaction mixture is then poured into ice-water (500 ml) and the resulting white solid filtered, washed with cold water, and then recrystallized from acetic acid to afford the product as a white solid; yield 72.2 g (85%); m.p. 119-120C.
Example X
2-Hydroxy-3-methoxy-6-nitrobenzald~y~
benzenesulfonate 2-Hydroxy-3-methoxybenzaldehyde-2-benzenesulfona~e (50 g, 171 mM) is added to nitric acid (500 ml) at 0C - 5C.
:

.
;` oRTH-388 ~L22~

The solution is kept five minutes at 5C and then poured into ice-water (1.5 L). The crude product, a tan solid, is filtered, washed with cold water, alcohol, and then recr~stallized from acetic acid (650 ml) to afford the product as a white solid; yield 30.3 g (52.6%); m.p. 152-154C.

Example Y
2-H~droxy-3-methoxy-6-nitrobenzaldehxde A slurry of 2-hydroxy-3-methoxy-6-nitrobenzaldehyde-2-benzenesulfonate (10.12 g, 30 mr~) in methanol (12Q ml) is heated to reflux. A solution of KOH (6 g) in water (2~ ml) and methanol (1~ ml) is added and the two phase mixture refluxed for 30 minutes. The light reddish preci-pitate which forms is filtered and then dissolved in boiling water (120 ml). Acidification of the hot aqueous solution with 10% aqueous HCl to pH~ 4 gives a yellow precipitate (5.0 g). Recrystallization from isopropyl alcohol affords the product as a yellow solid; yield 4.5 g (76.2%); m.p. 102-104~.

Example Z
2,3-Dimethoxy-6-nitrobenzaldehyde A slurry of NaH (16.0 g, 50% oily dispersion, 337 mM) in dimethylformamide (200 ml) was treated dropwise with a solution of 2-hydroxy 3-methoxy-6-nitrobenzaldehyde ~49.0 g, 248 mM) in DMF (300 ml) at such a rate that the temperature did not exceed 35C. The mixture is aged at room temperature for 1 hour and then a large excess of methyl iodide (100 ml) is added dropwise. A slight exothermic reaction occurs. The mixture is then stirred vigorously for 19 hours at room ~emperature. After the removal of excess methyl iodide, the reaction mixture is poured into ice-wa~er (1 1). The crude product, a brown ~2~6~

solid, is filtered, washed with cold water, and then recrystallized from isopropyl alcohol (700 ml) to a~ford the product as a tan solid; yield 27.9 g (53.3%);
m.p. 106-108~C.

2,3-Dimethoxy~6-nitrobenzaldehyde-ethyleneketal A mixture of 2,3-dimethoxy-6-nitrobenzaldehyde (16~0 g, 10 75 mM), ethylene glycol (64 g, 103 mM), and ~-toluenesul-fonic acid monohydrate (0.2 g) in benzene (750 ml) is refluxed in a Dean-Stark apparatus for 4S hours. The solution is then poured into water (1 1.). The organic phase is washed with saturated aqueous NaHCO3 (2x20 ml), dried over Na2SO4, filtere~, and the solvent removed in vacuo. The crude product is recrystallized from n--hexane (2 1.); yield 15.2 9 (78.2%); m.p. 74-76C.

Example BB
2-A~ino-5,6-dimethoxybenzaldehyde ethyleneketal A solution of 2,3-dimethoxy-6-nitrobenzaldehyde-ethylene-ketal (12.1 9, 62.7 mM) in ethyl ace~ate (350 ml) con~ain-ing sodium acetate (0.5 g) is treated with platinum oxide (1.0 g) and the mixture hydrogenated for 24 hours at ~50 psi. The solvent is removed in vacuo af~er filtering off the catalyst to give a pale brown oil. A~ter crystal-lization from n-hexane, the product is obtained as a tan solid; yield 12.8 g (85.1%); m.p. 78-80C.
Example CC
2-(N-Carbethoxyamino)-5,6-dimethoxy~ zaldehyde ethyleneketal 35 Ethylchloroformate (1.9 g, 17.5 mM) is added with stirring to 2-amino-5,6-dimethoxybenzaldehyde-ethyleneketal (1.6 g, 7.1 mM) dissolved in tetrahydrofuran ~50 ml). A
solution of sodium hydroxide in H2O (0.72 9 in 3.5 ml H2O) is added and the resulting solution is stirred for 2 hours at room te~perature. The ~etrahydrofuran is removed in vacuo and the residue extracted with CHC13 (2x100 ml).
The extracts are dried over ~la2SO4, filtered, and the solvent removed in vacuo. The crude product is recrystal--lized from n-hexane; yield 1.2 g (57.1%); m.p. gS-96C.
-Example DD
2-(N-Carbethox~amino)-5,6-dimethox~benzaldehyde 2-(N-Carbethoxyamino)-5,6-dimethoxybenzaldehyde-ethylene-ketal (5.0 g, 16.8 mM) is dissolved in acetone {36 ml) and aqueous HCl (3 ml of lN solution). The mixture is stirred at room temperature for 4 hours. The solvent is removed ln _acuo to give a yellow solid (3.9 g). Recrystalliza-tion from n-hexane gives the pure product as a yellow solid; yield 3.6 9 (84.7%); m.p. 86-88C.
Example EE
5,6-Dimethoxy-2(lH)-quinazolinone A stream of dry ammonia gas is passed through a solution of 2-(N-carbethoxyamino)-5,6-dimethoxybenzaldehyde (12.4 g, 48.9 mM) and ammonium acetate (95 g) maintained at 155-160C for 3 hours~ The reaction mixture is cooled and poured into an ice-water mixture. A tan solid formsO
The aqueous mixture is treated with NaCl (50 g) and then extracted with CHC13 (3x200 ml). The organic extracts are combined and the solvent is removed in vacuo to yield 9.2 9 of a pale brown oil~ Trituration of the oil with hot acetone gives the product as a yellow solid; yield 2.1 9 (20.8%); ~.p. 242-244C.

; ORTH-388 ~2~Z~

~xam~le FF
3,4-Dihydro-5!6-dimethoxy-4-met_~1-2(1H)quinazolinone To a partial solution of 5,6-dimethoxy-2(1H)quinazolinone S (10.0 g, 48.5 mM) in dry tetrahydrofuran (1100 ml) under nitrogen, is added at 0C over 20 minutes, an excess of methyl magnesium bromide in ether (62.60 ml of a 3.1 M
solution in ether, 194.06 mM). The reaction mixture is then removed from the cooling bath, allowed to reach room temperature and is stirred at room temperature for 16 hours. Additional methyl magnesium bro~ide is added (15.65 ~1 of a 3.1 M solution ln ether; 48.52 mM) and the reaction mixture is heated at reflux for 2 hours, cooled in an ice-water bath and an aqueous solution of NH4Cl (100 ml of saturated NH4Cl and 100 ml H~O) is added with stirring. After the addition is complete, 10% aqueous HCl is added until a pH of ~6.0 is reached. The layers are separated and the aqueous layer is extracted with CHCl3 (3x250 ml). The CHC13 extract is combined with the pre-viously separated tetrahydrofuran layer, and the combined organic layers are washed with a saturated aqueous solu-tion of NaCl (200 ml) and dried (Na2SO4). Filtration followed by concentration to ~250 ml affords an off-white precipitate which is filtered and recrystallized from isopropanol (200 ml) to give the product as a colorless solid; yield 9.7 9 (~7.8%), m.p. 210-212C.

Eample GG
5,6-Dimethoxy-4-meth~1-2(lH)~uinazolinone Potassium permanganate (25.6 ~, 162.38 mM) is added to a solution of 3,4-dihydro-5,6-dimethoxy-4-methyl-2(1H)quina-zolinone (18.04 9, 81.19 mM) in acetone (5.0 liters) and the mixture is stirred at room temperature (under nitro-gen, protected from light with aluminum foil) for 96hours. The brown precipitate which forms is filtered and washed with acetone (500 ml) and is partially dissolved in 2~

boiling water (1000 ml). The hot, aqueous solution (after filtration) is neutraliæed with 10~ aqueous HCl and then extracted with CHC13 (4x250 ml) and 10% isopropyl alcohol/ethyl acetate (4x250 ml). The CHC13 extracts are 5 dried (MYSOL,), filtered, and concentrated to 500 ml at which point a solid forms. The solid is filtered off and the filtrate is further concentrated in vacuo to give 3.25 9 of a tan solid which is chromatographed on a 350 g SilicAR column that has been prepared in CHC13 (500 ml 10 fractions). ~lution with 1/2% methanol/chloroform affords a yellow solid (1.92 9) which upon recrystallization from isopropanol (75 ml) affords the product as a yellow solid;
yield 0.940 g (5.3%); mp 230-232C.

15 When in the above procedure 3,4-dihydro-5,6-dimethoxy-4-trifluoromethyl-2(lH)quinazolinone, 3,4-dihydro-5,6-dimethoxy-4-isopropyl-2(1H)quinazolinone and 3,4-dihydro-4-cyclohexyl-5,6-dimethoxy-2(1H)quinazolinone are e~ployed in place of 3,4-dihydro-5,6-dimethoxy-4-methyl-2(1H)quina-20 zolinone the corresponding 5,6-dimethoxy-4-trifluoro-methyl-2(lH)quinazolinone, 5,6-dimethoxy-4-isopropyl-2(lH)quinazolinone and 4-cyclohexyl-5,6-dimethoxy 2(lH)-quinazolinone are obtained.

25 Example HH
2-(N-Carbethoxyamino)-5-methoxy-acetophenone Ethyl chloroformate (8.6 9, 080 m) is added cautiously with stirring to 2-amino-5-methoxyacetophenone (8.0 g, 30 0.0479 ~ while cooling the reaction mixture~ A solution of sodium hydroxide in H20 (3.2 g in 15 ml) is added slowly. The reaction becomes exothermic and all of the solids dissolve~ The yellow reaction mixture is removed from the ice bath and allowed to stir a~ room temperature 35 for 2 hours. The reaction mixture is then extracted with CHC13 (3X100 ml) dried over Na2SO4, filtered, and the solvent is removed in vaGuo to give a yellow solid.

~2~

Crystallization from hexane affords the product as a yellow solid; yield 7.4 g (65~); mp 90-92C.

Example II
S 6-Methoxy-4-methyl-2(lH)quinazolinone A stream of dry ammonia gas is passed for 3 hours through a solution of 2-tN-carbethoxyamino)-5-methoxy-acetophenone (14.0 g, 0.058 m) and ammonium acetate maintained at 155-160C. The reaction mixture is cooled and poured intoice-water ~750 ml) to give a dark orange solution. The solution is extracted with CH~C12 (3X500 ml) followed by ethyl acetate (2X500 ml) and n-butanol (2XS00 ml); the combined organic extracts are dried over Na2SO4 and the solvent is removed to give a brownish residue. The residue is slurried in acetone and the insoluble portion is filtered to give the product as a pale yellow solid;
yield 3.25 g, (25~); mp 232-236C dec.

Example JJ
4-Methyl-7-methoxy-2(lH~quinazolinone A mixture of l-acetyl-3~3-methoxyphenyl)urea (3205 g, 0.156 m) and polyphosphoric acid (912.5 g) is heated at 25 120-130C for 2 hours. Ater cooling to 50C the melt is poured on ice-water (2 liters), and ~he solution is made weakly basic with ammonia and left standing overnight.
The brownish-red precipitate which forms is filtered off, washed with cold water followed by hot aeetone, and crystallized from ethanol (after treatment with charcoal) to give the product as a p~le yellow solid; yield 11.5 g (39.1%); mp ~51-254C.

The 5,6-2(1H)quina~olinones having a substituent other than the methoxy group at C6 and C7 and a substituent other than lower alkyl at C4 are prepared according to the methods described for the preparation of the corresponding ORTH-388 6,7-2(1H)quinazolinones.

Claims (11)

1. The process for preparing a compound of the formula which comprises reacting a compound of the formula with ethylene glyco HOCH2CH2OH to form the corresponding 2,3-dialkoxy-6-nitrobenzaldehyde-ethyleneketal of the formula reacting the ethyleneketal with a reducing agent to form the corresponding 2-amino-5,6-dialkoxybenzaldehyde ethyleneketal of the formula reacting the aminobenzaldehyde ethyleneketal with an alkyl chloroformate of the formula ClCOOR

to form the corresponding 2-(N-carbethoxyamino) 5,6-dimethoxybenzaldehyde ethyleneketal of the formula reacting the 2-(N-carbethoxyamino) ethyleneketal with a mineral acid to form the 2-(N-carbethoxyamino)-5,6-dimethoxybenzaldehyde of the formula reacting the benzaldehyde with ammonia to form a quinazolinone of the formula reacting the quinazolinone with an alkyl magnesium bromide to form a quinazolinone of the formula and reacting the quinazolinone with an oxidizing agent; wherein R and R6 are lower alkyl.
2. The process according to claim 1 wherein R6 is methyl and R is ethyl.
3. The process according to claim 1 wherein the reducing agent is hydrogen and the oxidizing agent is potassium permanganate.
4. The process according to claim 1 wherein the mineral acid is hydrochloric acid.
5. The process for the preparation of 5,6-dimethoxy-4-methyl-2(1H)quinazolinone which comprises reacting 3,4-dihydro-4, 6-dimethoxy-4-2(1H)quinazolinone with an oxidizing agent.
6. A process for the preparation of 3,4-dihydro-5,6-dimethoxy-4-methyl-2(1H)quinazolinone which comprises reacting 5,6-dimethoxy-2(1H)quinazolinone with methyl magnesium bromide.
7. A process for the preparation of 5,6-dimethoxy-2(1H) quinazolinone which comprises reacting 2-(N-carbethoxyamino)-5, 6-dimethoxybenzaldehyde with ammonia.
8. A compound of the formula wherein R6 is lower alkyl whenever prepared or produced by the process of claim 1 or by any obvious chemical equivalent thereof.
9. 5,6-Dimethoxy-4-methyl-2(1H)quinazolinone whenever prepared or produced by the process of claim 5 or by any obvious chemical equivalent thereof.
10. 3,4-Dihydro-5,6-dimethoxy-4-methyl-2(1H)quinazolinone whenever prepared or produced by the process of claim 6 or by any obvious chemical equivalent thereof.
11. 5,6-Dimethoxy-2(1H)quinazolinone whenever prepared or produced by the process of claim 7 or by any obvious chemical equivalent thereof.
CA000509685A 1982-09-30 1986-05-21 Ortho substituted dihydroxy-2(1h)quinazolinone-1- alkanoic acids Expired CA1224468A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA000509685A CA1224468A (en) 1982-09-30 1986-05-21 Ortho substituted dihydroxy-2(1h)quinazolinone-1- alkanoic acids

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US430,552 1982-09-30
US06/430,552 US4490374A (en) 1982-09-30 1982-09-30 5,6-Dialkoxy-3,4-optionally substituted-2(1H)quinazolinones, composition and method of use
CA000437876A CA1215712A (en) 1982-09-30 1983-09-29 Ortho substituted dihydroxy-2(1h) quinazolinone-1- alkanoic acids
JP59058527A JPS60204770A (en) 1982-09-30 1984-03-28 Dihydroxy-2(1h)quinazoline-1-alkanoic acids
CA000509685A CA1224468A (en) 1982-09-30 1986-05-21 Ortho substituted dihydroxy-2(1h)quinazolinone-1- alkanoic acids

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA000437876A Division CA1215712A (en) 1982-09-30 1983-09-29 Ortho substituted dihydroxy-2(1h) quinazolinone-1- alkanoic acids

Publications (1)

Publication Number Publication Date
CA1224468A true CA1224468A (en) 1987-07-21

Family

ID=27167383

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000509685A Expired CA1224468A (en) 1982-09-30 1986-05-21 Ortho substituted dihydroxy-2(1h)quinazolinone-1- alkanoic acids

Country Status (1)

Country Link
CA (1) CA1224468A (en)

Similar Documents

Publication Publication Date Title
CA1215712A (en) Ortho substituted dihydroxy-2(1h) quinazolinone-1- alkanoic acids
DE3834204C2 (en)
CA2012628C (en) New fluoro-4 benzoic derivatives, process for their preparation and pharmaceutical compositions containing them
CA1066282A (en) .beta.-ADRENERGIC RECEPTOR BLOCKING AGENTS
DE69015541T2 (en) Quinoline derivatives, their production and use.
CH644112A5 (en) 3-AROMATIC-SUBSTITUTED-4 (3H) CHINAZOLINONES AND METHOD FOR THE PRODUCTION THEREOF.
JPH0471914B2 (en)
JP2003502278A (en) New N-oxide
US4639518A (en) Substituted quinazolinediones
US4656267A (en) Substituted 2(1H)-quinazolinone-1-alkanoic acids and esters
US4556739A (en) 3,4-Dialkoxy-2-alkylcarbonyl analino compounds
US4631283A (en) Ortho substituted dihydroxy-2(1H)quinazolinone-1-alkanoic acids
KR910003116B1 (en) Substituted ih-imidazoles
US4555571A (en) Substituted 2(1H)-quinazolinone-1-alkanoic acids and esters
US4771047A (en) Benzazepine derivatives
CA1224468A (en) Ortho substituted dihydroxy-2(1h)quinazolinone-1- alkanoic acids
CA1099712A (en) Antihypertensive polyfluorohydroxyisopropyl bicyclic and tricyclic carbostryrils
JPH01224364A (en) Production of herbicidal o-carboxyarylimidazolinones
US4617392A (en) 4-alkyl-5,6-methylenedioxy-2-1[H]-quinazolinones useful as cardiotonic agents
CA1138871A (en) Quinazol in-2-ones
US4302458A (en) Phthalidyl-isoquinoline derivatives
NZ205685A (en) Dihydroxy-2(1h)-quinazolinone-1-alkanoic acids and pharmaceutical compositions
JP2003506358A (en) Isoquinoline derivatives, pharmaceutical compositions containing the derivatives and methods for producing active substances
CA1125170A (en) Quinazol in -2-ones
KR840000152B1 (en) Process for preparing 2-azaerythrinan derivatives

Legal Events

Date Code Title Description
MKEX Expiry